Sabir Mukhametshin

Mr. Sabir Mukhametshin

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
Emil BulatovEmil Bulatov
Emil Bulatov
SMSabir Mukhametshin
Sabir Mukhametshin
IGIrina Ganeeva
Irina Ganeeva
EGElvina M. Gilyazova
Elvina M. Gilyazova
ESElvira T. Siraeva
Elvira T. Siraeva
Emil BulatovEmil Bulatov
Emil Bulatov
Cell therapy is at the forefront of biomedicine in oncology and regenerative medicine. However, there are still significant challenges to their wider clinical application such as limited efficacy, side effects, and logistical difficulties. One of the potential approaches that could overcome these problems is based on extracellular vesicles (EVs) as a cell-free therapy modality. One of the major obstacles in the translation of EVs into practice is their low yield of production, which is insufficient to achieve therapeutic amounts. Here, we evaluated two primary approaches of artificial vesicle induction in primary T cells and the SupT1 cell line—cytochalasin B as a chemical inducer and ultrasonication as a physical inducer. We found that both methods are capable of producing artificial vesicles, but cytochalasin B induction leads to vesicle yield compared to natural secretion, while ultrasonication leads to a three-fold increase in particle yield. Cytochalasin B induces the formation of vesicles full of cytoplasmic compartments without nuclear fraction, while ultrasonication induces the formation of particles rich in membranes and membrane-related components such as CD3 or HLAII proteins. The most effective approach for T-cell induction in terms of the number of vesicles seems to be the combination of anti-CD3/CD28 antibody activation with ultrasonication, which leads to a seven-fold yield increase in particles with a high content of functionally important proteins (CD3, granzyme B, and HLA II).

Verified
Journal Article
Open access
PDF file
VCVitaly Chasov
Vitaly Chasov
SMSabir Mukhametshin
Sabir Mukhametshin
AVAigul Valiullina
Aigul Valiullina
YSYulia Skibo
Yulia Skibo
MZMaral Zhumabekova
Maral Zhumabekova
Emil BulatovEmil Bulatov
Emil Bulatov
Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous system (CNS) characterized by the destruction of the myelin sheath around nerve cells. The prevalence and serious consequences of MS highlight the shortcomings of existing treatments and the importance of developing innovative therapeutic approaches. Based on successful pilot studies in patients and an experimental autoimmune encephalomyelitis (EAE) mouse model, CAR-T cells offer a novel therapeutic mechanism by directly targeting and eliminating B cells, overcoming the shortcomings of antibody-mediated B cell depletion, which is unable to penetrate deep into the CNS. Recent discoveries have also revealed an important role for the gut microbiota in maintaining immune homeostasis. In a state of homeostasis, there is a symbiotic relationship between host factors and the microbiota that helps to maintain a healthy state. However, alterations in the composition and function of the gut microbiota, known as gut dysbiosis, can disrupt this homeostasis. The microbiota, through its metabolites, can influence not only internal processes in the gut but also the CNS in MS. Therapeutic interventions that help restore the balance of the gut microbiota may be a promising additional treatment to existing therapies to alleviate symptoms and promote remission in patients with MS.